24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
EpiPen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:22
XTEND lays off 10% of workforce after losing 75% of its value since $1.5 billion NYSE debut
17:04
Full list of Israeli startup M&As in 2026
17:00
Israeli digital health company TailorMed acquired in $250 million deal
15:41
Marvell acquires Lumentum in $115 billion push to dominate AI connectivity
More stories
Buzz
Most popular
Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company
4
Israeli startup Coldi is deploying AI agents to take over the cold call
5
Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief
More news
EpiPen
4 stories about EpiPen
Teva Jumps on NYSE on a Bit of Good News
21.08.19
|
Hezi Sternlicht
An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18
|
Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Teva’s Generic EpiPen Now Available in the U.S. in Limited Numbers
28.11.18
|
Lilach Baumer
In August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
26.08.18
|
Dror Reich
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month